Upadacitinib doubles ASAS 40 response vs. placebo in ankylosing spondylitis
ATLANTA – The selective JAK1 inhibitor upadacitinib had a rapid effect, with a clear difference emerging between the treatment and placebo groups within 2 weeks in the SELECT-AXIS 1 study.